Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.

Resilience is leading the pursuit of novel medicines by revolutionizing how they’re made, funded and scaled.

Resilience was founded in 2020 by Rahul Singhvi, Robert Nelsen and Patrick Y. Yang. The company is headquartered in La Jolla, CA, with 10 facilities across North America,


Resilience focuses on five therapeutic modalities – biologics, vaccines, nucleic acids and cell and gene therapies. The company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely and at scale.


Resilience‘s flexible business model enables it to partner with customers of any size and across therapeutic modalities, through fee-for-service arrangements, value-share agreements and new company creation/incubation projects.


Resilience works with industry customers and partners, government agencies, academic institutions and non-profit organizations. Current customers include Takeda’s Plasma-Derived Therapies Business Unit, U.S. Department of Defense, among others.


Resilience is backed by ARCH Venture Partners, 8VC, General Catalyst, GV, NEA, Lightspeed Venture Partners, Founders Fund, Charles River Ventures, RA Capital Management, and others. The company raised $625M in Series D round on Jun 06, 2022. This brings Resilience's total funding to $2B to date.



  • Year founded: 2020
  • Funding Info: $2B over 4 Rounds (Latest Funding Type: Series D)
  • Yearly Revenue: NA
  • Employee Size: 1,001-5,000
  • Business Valuation: NA
  • City/Town: La Jolla
  • State: California
  • Country: United States
Related businesses